Sarepta Therapeutics (SRPT) Shares are Down -4.17%

Sarepta Therapeutics (SRPT) has risen sharply, recording gains of 21.09% in the past 4 weeks. However, the stock has corrected -4.17% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 19.86% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.51% and the 50-Day Moving Average is 19.28%. Sarepta Therapeutics (NASDAQ:SRPT): stock turned positive on Friday. Though the stock opened at $24.83, the bulls momentum made the stock top out at $25.39 level for the day. The stock recorded a low of $24.72 and closed the trading day at $25.26, in the green by 1.85%. The total traded volume for the day was 1,214,768. The stock had closed at $24.8 in the previous days trading.


The company Insiders own 10.9% of Sarepta Therapeutics shares according to the proxy statements. Institutional Investors own 78.57% of Sarepta Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of 4.44%. Also, Wedbush reiterates its view on Sarepta Therapeutics (NASDAQ:SRPT) according to the research report released by the firm to its investors. The shares have now been rated Outperform by the stock experts at the ratings house. Wedbush maintains the current price target of $36 per share on Sarepta Therapeutics . The rating by the firm was issued on July 20, 2016.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *